<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A 68-year-old woman with <z:e sem="disease" ids="C0040028" disease_type="Disease or Syndrome" abbrv="">essential thrombocythemia</z:e> had been treated with hydroxycarbamide and aspirin for 13 years </plain></SENT>
<SENT sid="1" pm="."><plain>She exhibited the <z:hpo ids='HP_0003678'>rapid progression</z:hpo> of <z:hpo ids='HP_0001903'>anemia</z:hpo>, and a bone marrow examination showed <z:mpath ids='MPATH_589'>dysplasia</z:mpath> of the erythroid cells, myeloid cells, and megakaryocytes </plain></SENT>
<SENT sid="2" pm="."><plain>Karyotype analysis indicated complex abnormalities including der (5;21)(p10;q10) </plain></SENT>
<SENT sid="3" pm="."><plain>She was diagnosed with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess blasts-1 (<z:e sem="disease" ids="C1318550" disease_type="Neoplastic Process" abbrv="">RAEB-1</z:e>) </plain></SENT>
<SENT sid="4" pm="."><plain>Lenalidomide was started, but no improvement in <z:hpo ids='HP_0001903'>anemia</z:hpo> was recorded </plain></SENT>
<SENT sid="5" pm="."><plain>Lenalidomide was discontinued due to <z:hpo ids='HP_0001880'>eosinophilia</z:hpo>, basophilia, and a <z:hpo ids='HP_0000988'>skin rash</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain><z:chebi fb="0" ids="2038">Azacitidine</z:chebi> was administered </plain></SENT>
<SENT sid="7" pm="."><plain>The patient became transfusion independent, and a complete cytogenetic response was achieved with three courses of <z:chebi fb="0" ids="2038">azacitidine</z:chebi> </plain></SENT>
<SENT sid="8" pm="."><plain>However, disease progression to <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) was observed after an additional two courses of <z:chebi fb="0" ids="2038">azacitidine</z:chebi>, which was resistant to induction chemotherapy </plain></SENT>
<SENT sid="9" pm="."><plain>The patient died five months later from <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> transformation </plain></SENT>
<SENT sid="10" pm="."><plain><z:chebi fb="0" ids="2038">Azacitidine</z:chebi> may be effective in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> transformed from <z:e sem="disease" ids="C0040028" disease_type="Disease or Syndrome" abbrv="">essential thrombocythemia</z:e>, and also in lenalidomide-resistant <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> with the deletion of 5q </plain></SENT>
</text></document>